NCT07141511

A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults

A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered simultaneously and the effect of food on how the body processes the fixed-dose combination tablet.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	BG-71332	Administered orally
DRUG	Zanubrutinib	Administered orally
DRUG	Sonrotoclax	Administered orally

Timeline

• Start date: 2025-09-24
• Primary completion: 2026-02-23
• Completion: 2026-02-23
• First posted: 2025-08-26
• Last updated: 2026-03-25

Locations

1 site across 1 country: Australia